NCT06525220 2026-03-27
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Phase 3 Recruiting
Merus B.V.
AstraZeneca
EMD Serono
Inovio Pharmaceuticals
Swedish Orphan Biovitrum
Sanofi
Vical